What “success rate” usually means for Cosentyx (secukinumab)
People use “success rate” to mean different outcomes in Cosentyx studies, most often:
- How many patients achieve a major skin response (for plaque psoriasis, commonly PASI-75 or PASI-90)
- How many achieve joint improvement (for psoriatic arthritis or axial spondyloarthritis, often ACR responses such as ACR20/50, or measures like ASAS)
- How many reach low disease activity/remission
Because these targets vary by condition and trial, “success rate” isn’t one single number.
Cosentyx for plaque psoriasis: what response rates look like
In phase 3 trials for moderate-to-severe plaque psoriasis, Cosentyx’s effectiveness is typically reported as the share of patients reaching PASI-75 (and often higher thresholds like PASI-90) at defined timepoints (commonly week 16 or week 52, depending on the study). Your actual “success rate” depends on:
- Your baseline severity
- The specific dose regimen (e.g., 150 mg vs 300 mg)
- Whether the question is about short-term skin clearance vs longer-term durability
Cosentyx for psoriatic arthritis: how joint “success” is measured
For psoriatic arthritis, trials generally report:
- ACR response rates (ACR20/50/70) and
- Improvements in skin (often PASI responses) at the same timepoints
If you’re comparing “success,” you’ll want the ACR level and whether patients were biologic-naive or had prior biologic exposure, since response rates tend to be higher in biologic-naive populations.
Cosentyx for ankylosing spondylitis / non-radiographic axial spondyloarthritis
For axial spondyloarthritis, “success rate” is usually based on composite clinical measures (commonly including pain, function, and inflammation outcomes such as ASAS criteria). The time to response also matters: many patients see improvements within the first few months, but longer follow-up is needed to judge durability.
What counts as a good personal outcome?
Clinically, patients often consider Cosentyx a “success” if they reach sustained control such as:
- Major skin clearing (often at least PASI-75, with PASI-90 seen as deeper response)
- Meaningful joint symptom improvement (for example, ACR20 or better in trials)
- Lower disease activity over time rather than a short-lived response
If you tell me your condition, I can give the most relevant “success rate”
Cosentyx’s “success rate” depends heavily on which disease you mean. Reply with:
1) Which condition: plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis
2) What outcome you mean by success: skin clearance (PASI), joint response (ACR), or “remission/low disease activity”
3) If you know it: dose (150 mg or 300 mg) and whether the patient had prior biologics
Then I can translate the trial endpoints into the specific success-rate numbers that match your situation.